This report provides an overview of a horizon scanning project undertaken on behalf of the Early Stage Products work stream of the Accelerated Access Collaborative (AAC) to identify potential HITs in the pipeline to ensure the smooth adoption of these technologies into the NHS when they become available. The scan also aimed to gather additional information on the genomic/molecular targets of these potential HITs in order to support the development of the genomic testing infrastructure and capability of the NHS.
Horizon Scan for Histology Independent Technologies
Histology-Independent Therapies (HITs) for cancer, or Tumour-Agnostic Therapies are recent innovations in oncology wherein treatment is based on the cancer’s genetic and molecular alterations rather than cancer type and/or site of origin.